Article

Curcumin: From molecules to markets

WenJun Zhang
School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China; International Academy of Ecology and Environmental Sciences, Hong Kong
E-mail: zhwj@mail.sysu.edu.cn, wjzhang@iaees.org

Received 22 February 2026; *Accepted 10 March 2026*; *Published online 30 March 2026*; *Published 1 September 2027*

Abstract
Curcumin, the principal curcuminoid derived from the rhizome of *Curcuma longa* (turmeric), has been a molecule of immense scientific interest for decades. This review provides a comprehensive overview of curcumin, encompassing its historical context, detailed pharmacological properties, underlying molecular mechanisms, clinical trial outcomes, and its journey in industrial applications. Despite its promising multifaceted bioactivities—including potent anti-inflammatory, antioxidant, anticancer, antimicrobial, and neuroprotective effects—its therapeutic translation has been hampered by poor aqueous solubility, low systemic bioavailability, and rapid metabolism. Advances in nanoparticle-based delivery systems and formulation technologies are actively addressing these limitations. While numerous preclinical studies robustly support its health benefits, clinical evidence remains mixed, necessitating larger, well-designed trials. In the non-pharmaceutical sector, curcumin enjoys widespread use as a natural colorant, preservative, and nutraceutical. Future research should focus on optimizing delivery, identifying specific biomarkers for patient stratification, and conducting rigorous phase III clinical trials to definitively establish its efficacy in various disease conditions.

Keywords curcumin; turmeric; bioavailability; clinical trials; nanodelivery; nutraceutical; inflammation; oxidative stress.

Ornamental and Medicinal Plants
ISSN 2522-3682
URL: http://www.iaees.org/publications/journals/omp/online-version.asp
RSS: http://www.iaees.org/publications/journals/omp/rss.xml
E-mail: omp@iaees.org
Editor-in-Chief: WenJun Zhang
Publisher: International Academy of Ecology and Environmental Sciences

1 Introduction

Curcumin [(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] is a lipophilic polyphenol responsible for the vibrant yellow hue of turmeric (*Curcuma longa* L.), a plant belonging to the Zingiberaceae family (Ammon & Wahl, 1991). For centuries, turmeric has held a sacred and medicinal position in Ayurveda, traditional Chinese medicine, and other cultural healing practices, primarily used for treating conditions like inflammation, wounds, and digestive disorders. In the modern era, curcumin has transitioned from a traditional remedy to a subject of intense biomedical investigation. Since its isolation in the 19th century and structural

elucidation in the 20th century, over ten thousand peer-reviewed publications have explored its potential in combating a vast array of diseases, ranging from cancer and neurodegenerative disorders to metabolic syndrome and chronic inflammatory conditions (Gupta et al., 2013). Its appeal lies in its pleiotropic nature—ability to modulate multiple signaling pathways—coupled with an exceptional safety profile even at high doses. This review synthesizes the journey of curcumin from its historical roots to its current status in science, medicine, and industry, critically evaluating the evidence and outlining future directions.

2 Historical Background and Isolation

The use of turmeric in South Asia dates back over 4000 years. It was not only a culinary spice but also a component of religious ceremonies and a therapeutic agent. The first recorded evidence of its medicinal use appears in *Sushruta Samhita* (circa 250 BCE), recommending an ointment containing turmeric to relieve the effects of poisoned food.

The scientific study of turmeric began in the 19th century. In 1815, Vogel and Pelletier reported the isolation of a "yellow coloring-matter" from turmeric rhizomes, which they named "curcumin". Later, in 1870, the same substance was isolated independently by Daube. The chemical structure of curcumin, however, remained elusive for several more decades. Milestone work by Lampe and Milobędzka in 1910 proposed a structure, which was finally confirmed and its synthesis reported by Srinivasan in 1953. This synthesis established curcumin as diferuloylmethane. For much of the early 20th century, curcumin was primarily of interest as a coloring agent and a cheap pH indicator. The paradigm shift began in the mid-20th century when its biological activities, particularly anti-inflammatory properties, started to be systematically investigated.

3 Pharmacological Properties and Molecular Mechanisms

Extensive *in vitro* and *in vivo* studies have elucidated a wide spectrum of biological activities for curcumin. Its effects are primarily mediated through the modulation of numerous transcription factors, growth factors, inflammatory cytokines, protein kinases, and other enzymes.

3.1 Anti-inflammatory and Antioxidant Activities

These are the most well-characterized properties. Curcumin is a potent scavenger of reactive oxygen species (ROS) and reactive nitrogen species (RNS) (Menon & Sudheer, 2007). More importantly, it upregulates the expression of endogenous antioxidant enzymes like heme oxygenase-1 (HO-1), superoxide dismutase (SOD), and catalase via activation of the Nrf2-ARE pathway.

Its anti-inflammatory action is profound. Curcumin directly inhibits key pro-inflammatory enzymes such as cyclooxygenase-2 (COX-2), lipoxygenase (LOX), and inducible nitric oxide synthase (iNOS). Its most significant molecular target is the transcription factor Nuclear Factor-kappa B (NF-κB), a master regulator of inflammation. Curcumin blocks the phosphorylation and degradation of IκBα, thereby preventing NF-κB translocation to the nucleus and the subsequent expression of genes encoding TNF-α, IL-1, IL-6, COX-2, and iNOS (Aggarwal et al., 2007). It also suppresses the activation of mitogen-activated protein kinase (MAPK) and Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathways.

3.2 Anticancer Potential

Curcumin exhibits anticancer effects at all stages of carcinogenesis: initiation, promotion, and progression. It induces apoptosis in cancer cells by modulating the expression of Bcl-2 family proteins, activating caspases, and inducing PARP cleavage. It inhibits proliferation by downregulating cyclin D1 and arresting the cell cycle. Curcumin is also a potent anti-angiogenic agent, suppressing vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Furthermore, it inhibits metastasis by downregulating matrix

metalloproteinases (MMPs) and adhesion molecules (Gupta et al., 2018). It affects multiple oncogenic pathways, including NF-κB, STAT3, Wnt/β-catenin, and PI3K/Akt.

3.3 Neuroprotective Effects

Curcumin's ability to cross the blood-brain barrier, albeit limited, underpins its neuroprotective potential. It reduces oxidative stress and neuroinflammation in the brain. Notably, it can bind to and disaggregate beta-amyloid plaques, a hallmark of Alzheimer's disease (AD), and inhibit the hyperphosphorylation of tau protein, which forms neurofibrillary tangles (Mishra & Palanivelu, 2008). It also enhances brain-derived neurotrophic factor (BDNF) levels, supporting neuronal survival and plasticity.

3.4 Antimicrobial and Wound Healing Properties

Curcumin exhibits broad-spectrum antimicrobial activity against bacteria (e.g., *Staphylococcus aureus*, *Pseudomonas aeruginosa*), viruses, and fungi. Its mechanism involves disrupting bacterial cell membranes and biofilm formation. In wound healing, particularly relevant to diabetic wounds, curcumin's triad of anti-inflammatory, antioxidant, and antimicrobial actions creates a conducive microenvironment. It promotes fibroblast proliferation, collagen deposition, angiogenesis, and re-epithelialization, driving the wound through the inflammatory, proliferative, and remodeling phases effectively (Tu & Lin, 2021).

3.5 Metabolic and Cardiovascular Benefits

Curcumin improves insulin sensitivity, reduces hyperglycemia, and ameliorates diabetic complications. It activates AMP-activated protein kinase (AMPK), enhances glucose uptake, and protects pancreatic β-cells. In cardiovascular health, it improves endothelial function, reduces LDL oxidation, and decreases markers of inflammation like C-reactive protein (CRP), thereby mitigating atherosclerosis.

4 The Bioavailability Challenge and Delivery Strategies

A critical obstacle to curcumin's clinical success is its intrinsically poor pharmacokinetic profile. It has low solubility in water, undergoes rapid metabolism (via reduction and conjugation) in the liver and intestinal wall, and is quickly eliminated from the body, resulting in very low systemic plasma and tissue levels (Anand et al., 2007).

To overcome this, extensive research has focused on novel formulation strategies:

- **Lipid-based Systems:** Phospholipid complexes, liposomes, and nanoemulsions enhance solubility and lymphatic absorption.
- **Nanoparticle Encapsulation:** Polymeric nanoparticles (e.g., PLGA), solid lipid nanoparticles, and micelles significantly improve stability, bioavailability, and allow for targeted delivery.
- **Adjuvants:** Co-administration with piperine (from black pepper), a known inhibitor of glucuronidation, can boost serum levels.
- **Structural Analogs:** Synthesizing more stable and bioavailable derivatives, such as difluorinated curcumin (CDF), is an active area of research.
- **Curcumin Phytosome® and Theracurmin®:** These are patented, commercially available formulations with clinically demonstrated enhanced bioavailability compared to standard curcumin powder.

5 Clinical Trials: Evidence and Outcomes

Clinical translation has yielded a complex picture, with evidence varying across different conditions.

5.1 Inflammation and Arthritis

Several randomized controlled trials (RCTs) show promise. In patients with osteoarthritis, curcumin extracts have been found to reduce pain and improve physical function comparably to non-steroidal anti-inflammatory

drugs (NSAIDs) like ibuprofen, but with fewer gastrointestinal side effects (Daily et al., 2016). In rheumatoid arthritis, curcumin supplementation reduced disease activity scores and swelling.

5.2 Metabolic Syndrome and Diabetes

RCTs indicate that curcumin can effectively lower fasting blood glucose, HbA1c, and insulin resistance in prediabetic and type 2 diabetic populations. It also improves lipid profiles and reduces markers of oxidative stress and inflammation (Chuengsamarn, Rattanamongkolgul, Phonrat, Tungtrongchitr, & Jirawatnotai, 2014). Its role in ameliorating diabetic microvascular complications, like nephropathy and retinopathy, is supported by preliminary clinical data.

5.3 Neurodegenerative Diseases

A pivotal 18-month, double-blind, placebo-controlled trial in adults with mild, age-related memory decline found that a bioavailable form of curcumin led to significant improvements in memory and attention. PET scans also showed significantly less amyloid and tau accumulation in brain regions controlling mood and memory compared to placebo (Small et al., 2018). Larger trials in Alzheimer's patients are underway.

5.4 Cancer

Clinical trials in cancer have been mostly phase I/II, focusing on safety, pharmacokinetics, and biomarker modulation. Curcumin has been shown to be safe even at high doses (up to 12 g/day). Evidence for efficacy is emerging but not definitive. For instance, in patients with colorectal cancer, curcumin reduced the number of aberrant crypt foci. It has shown potential in reducing skin lesions in precancerous conditions. However, robust phase III trials demonstrating survival benefits are lacking (Howells et al., 2019).

5.5 Other Conditions

Positive effects have been observed in clinical trials for depression, ulcerative colitis, peptic ulcers, and skin diseases like psoriasis. The results, while encouraging, often come from small-scale studies and require validation.

6 Industrial Applications and Market Consumption

Beyond therapeutics, curcumin has a substantial global market driven by its applications in food, cosmetics, and dietary supplements.

- **Food Industry:** As a natural food colorant (E100), it is extensively used in dairy products, beverages, confectionery, and mustard. Its antioxidant property also acts as a natural preservative.
- **Nutraceuticals and Dietary Supplements:** This is the largest segment. Curcumin is marketed worldwide for joint health, digestion, immune support, and general wellness, often formulated with bioavailability enhancers.
- **Cosmetics:** Incorporated into skincare products for its anti-inflammatory and antioxidant benefits, targeting acne, aging, and pigmentation.

The global curcumin market is valued in the hundreds of millions of US dollars and continues to grow, fueled by consumer preference for natural products.

7 Future Perspectives and Conclusion

The journey of curcumin from a kitchen spice to a biomedical superstar is remarkable, yet its path forward requires strategic navigation. Key future directions include:

1. **Precision Delivery:** Continued innovation in nanotechnology and targeted delivery systems to ensure sufficient concentrations reach diseased tissues.
2. **Rigorous Clinical Validation:** Conducting large-scale, multicenter, long-term phase III RCTs with standardized, bioavailable formulations in specific patient populations.

3. **Mechanistic Clarity in Humans:** Moving beyond preclinical models to better understand the primary molecular targets and pharmacodynamic effects of curcumin in the human body.
4. **Combination Therapy:** Exploring curcumin as an adjuvant to enhance the efficacy and reduce the toxicity of conventional chemotherapy, radiotherapy, and other drugs.
5. **Regulatory Standardization:** Establishing clear guidelines for quality, dosage, and health claims for curcumin-based nutraceuticals.

In conclusion, curcumin is a molecule of extraordinary promise with a compelling safety record. Its pleiotropic pharmacology addresses the complex, multifactorial nature of many chronic diseases. While the "curcumin paradox"—high activity in labs but variable outcomes in clinics—primarily stems from pharmacokinetic limitations, advanced science is providing solutions. The coming decade will be crucial in determining whether this ancient polyphenol can fulfill its modern therapeutic potential and transition from a versatile nutraceutical to an evidence-based medicine for specific indications.

References

Aggarwal BB, Sundaram C, Malani N, Ichikawa H. 2007. Curcumin: the Indian solid gold. Advances in Experimental Medicine and Biology, 595: 1–75

Ammon HP, Wahl MA. 1991. Pharmacology of *Curcuma longa*. Planta Medica, 57(1): 1–7

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. 2007. Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics, 4(6): 807–818

Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. 2014. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. The Journal of Nutritional Biochemistry, 25(2): 144–150

Daily JW, Yang M, Park S. 2016. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. Journal of Medicinal Food, 19(8): 717–729

Gupta SC, Kunnumakkara AB, Aggarwal S, Surh YJ. 2018. Curcumin: A potential candidate for multitarget cancer therapy. Biochemical Pharmacology, 147: 1

Gupta SC, Patchva S, Aggarwal BB. 2013. Therapeutic roles of curcumin: lessons learned from clinical trials. The AAPS Journal, 15(1): 195–218

Howells LM, Iwuji CO, Irving GR, Barber S, Walter H, Sidat Z, et al. 2019. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial. The Journal of Nutrition, 149(7): 1133–1139

Menon VP, Sudheer AR. 2007. Antioxidant and anti-inflammatory properties of curcumin. Advances in Experimental Medicine and Biology, 595: 105–125

Mishra S, Palanivelu K. 2008. The effect of curcumin (turmeric) on Alzheimer's disease: An overview. Annals of Indian Academy of Neurology, 11(1): 13–19

Small GW, Siddarth P, Li Z, Miller KJ, Ercoli L, Emerson ND, et al. 2018. Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: A double-blind, placebo-controlled 18-month trial. The American Journal of Geriatric Psychiatry, 26(3): 266–277

Tu Z, Lin C. 2021. Research advances on the effects and mechanism of curcumin in promoting diabetic wound healing. Chinese Journal of Burns, 37(4): 381–384